MGMT and glioblastoma: A recent randomized phase II trial (VELIPARIB with Radiation Therapy and Temozolomide in Unmethylated MGMT Glioblastoma; VERTU) demonstrated that the PARP inhibitor veliparib, combined with TMZ and RT, improved PFS in MGMT-unmethylated patients (PFS-6m 46% vs. 31% in standard arm), pending phase III confirmation [39].